Zivo Bioscience Net Debt Growth & History (ZIVO)
Zivo Bioscience's net debt was −$1.5M for fiscal 2024.
View full Zivo Bioscience company overviewZivo Bioscience annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.5M | −$1.4M | — |
| 2023 | 2023-12-31 | −$168,038 | $1.3M | — |
| 2022 | 2022-12-31 | −$1.5M | $7.2M | — |
| 2021 | 2021-12-31 | −$8.6M | −$13.7M | — |
| 2020 | 2020-12-31 | $5.1M | $5.4M | — |
| 2019 | 2019-12-31 | −$346,111 | — | — |
| 2016 | 2016-12-31 | $2.7M | −$1.9M | −41.75% |
| 2015 | 2015-12-31 | $4.6M | $4.3M | +1844.41% |
| 2014 | 2014-12-31 | $235,659 | −$162,048 | −40.75% |
| 2013 | 2013-12-31 | $397,707 | −$149,054 | −27.26% |
| 2012 | 2012-12-31 | $546,761 | $341,382 | +166.22% |
| 2011 | 2011-12-31 | $205,379 | $116,919 | +132.17% |
| 2010 | 2010-12-31 | $88,460 | — | — |
Zivo Bioscience quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $228,615 | $365,991 | — |
| Q2 2025 | 2025-06-30 | $290,919 | $242,465 | +500.40% |
| Q1 2025 | 2025-03-31 | $52,512 | $112,120 | — |
| Q4 2024 | 2024-12-31 | −$1.5M | −$1.4M | — |
| Q3 2024 | 2024-09-30 | −$137,376 | $1.2M | — |
| Q2 2024 | 2024-06-30 | $48,454 | −$139,006 | −74.15% |
| Q1 2024 | 2024-03-31 | −$59,608 | −$33,116 | — |
| Q4 2023 | 2023-12-31 | −$168,038 | $1.3M | — |
| Q3 2023 | 2023-09-30 | −$1.3M | $1.7M | — |
| Q2 2023 | 2023-06-30 | $187,460 | $4.9M | — |
| Q1 2023 | 2023-03-31 | −$26,492 | $6.4M | — |
| Q4 2022 | 2022-12-31 | −$1.5M | $7.2M | — |
| Q3 2022 | 2022-09-30 | −$3.0M | $7.7M | — |
| Q2 2022 | 2022-06-30 | −$4.7M | $6.2M | — |
| Q1 2022 | 2022-03-31 | −$6.4M | −$6.2M | — |
| Q4 2021 | 2021-12-31 | −$8.6M | −$13.7M | — |
| Q3 2021 | 2021-09-30 | −$10.8M | −$10.7M | — |
| Q2 2021 | 2021-06-30 | −$10.9M | −$10.7M | — |
| Q1 2021 | 2021-03-31 | −$206,828 | −$196,785 | — |
| Q4 2020 | 2020-12-31 | $5.1M | $5.4M | — |
| Q3 2020 | 2020-09-30 | −$55,368 | — | — |
| Q2 2020 | 2020-06-30 | −$118,869 | — | — |
| Q1 2020 | 2020-03-31 | −$10,043 | — | — |
| Q4 2019 | 2019-12-31 | −$346,111 | — | — |
| Q1 2017 | 2017-03-31 | $13.0M | $8.4M | +181.92% |
| Q4 2016 | 2016-12-31 | $2.7M | −$1.9M | −41.75% |
| Q3 2016 | 2016-09-30 | $6.2M | $5.8M | +1377.12% |
| Q2 2016 | 2016-06-30 | $4.8M | $4.0M | +459.97% |
| Q1 2016 | 2016-03-31 | $4.6M | $4.0M | +628.98% |
| Q4 2015 | 2015-12-31 | $4.6M | $4.3M | +1844.41% |
| Q3 2015 | 2015-09-30 | $421,943 | $42,114 | +11.09% |
| Q2 2015 | 2015-06-30 | $864,987 | $259,908 | +42.95% |
| Q1 2015 | 2015-03-31 | $634,775 | −$278,809 | −30.52% |
| Q4 2014 | 2014-12-31 | $235,659 | −$162,048 | −40.75% |
| Q3 2014 | 2014-09-30 | $379,829 | $118,344 | +45.26% |
| Q2 2014 | 2014-06-30 | $605,079 | $460,299 | +317.93% |
| Q1 2014 | 2014-03-31 | $913,584 | — | — |
| Q4 2013 | 2013-12-31 | $397,707 | −$149,054 | −27.26% |
| Q3 2013 | 2013-09-30 | $261,485 | −$616,795 | −70.23% |
| Q2 2013 | 2013-06-30 | $144,780 | −$478,627 | −76.78% |
| Q4 2012 | 2012-12-31 | $546,761 | $341,382 | +166.22% |
| Q3 2012 | 2012-09-30 | $878,280 | $556,462 | +172.91% |
| Q2 2012 | 2012-06-30 | $623,407 | $364,521 | +140.80% |
| Q1 2012 | 2012-03-31 | $432,588 | — | — |
| Q4 2011 | 2011-12-31 | $205,379 | $116,919 | +132.17% |
| Q3 2011 | 2011-09-30 | $321,818 | — | — |
| Q2 2011 | 2011-06-30 | $258,886 | — | — |
| Q4 2010 | 2010-12-31 | $88,460 | — | — |
Zivo Bioscience net debt trends
Over the last five fiscal years, Zivo Bioscience's net debt decreased from −$346,111 to −$1.5M, a change of −$1.2M. The latest reported quarter, Q3 2025, shows $228,615.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zivo Bioscience source filings ↗